Skip to main content

Table 2 Metformin effects on vasculoprotection

From: Metformin: an old but still the best treatment for type 2 diabetes

Study

Design

Duration

Key findings

UKPDS 33 [18]

Prospective

10 yr

Significant reduction in all-cause mortality, diabetes related mortality, and any end-point related to diabetes.

Sgambato et al.[72]

Retrospective

3 yr

Trend towards reduction in angina symptoms (p = 0.051). Significant lower re-infarction rates.

Johnson et al.[24]

Retrospective

9 yr

Reduction of all-cause mortality and of cardiovascular mortality

Kao et al.[74]

Prospective

2 yr

Significant risk reduction for any clinical event, myocardial infarction and all-cause mortality

Jadhav et al.[76]

Prospective

8 weeks

Improved maximal ST depression, Duke score, and chest pain incidence

Kooy et al.[75]

Prospective

4, 3 yr

Reduction of the risk of developing macrovascular disease